We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+11.74%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$252M
AUM Growth
-$86.3M
Cap. Flow
-$109M
Cap. Flow %
-43.42%
Top 10 Hldgs %
38.06%
Holding
113
New
35
Increased
12
Reduced
16
Closed
45

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$11M
2
LH icon
Labcorp
LH
+$9.27M
3
MRK icon
Merck
MRK
+$8.29M
4
LIVN icon
LivaNova
LIVN
+$7.92M
5
ATHN
Athenahealth, Inc.
ATHN
+$5.37M

Top Sells

Rank Stock Value
1
HOLX
Hologic
HOLX
+$10.7M
2
BCR
CR Bard Inc.
BCR
+$9.32M
3
GSK icon
GSK
GSK
+$8.25M
4
UNH icon
UnitedHealth
UNH
+$7.79M
5
CNC icon
Centene
CNC
+$7.73M

Sector Composition

Rank Sector Weight
1 Healthcare 65.96%
2 Industrials 2.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEOS
51
DELISTED
Neos Therapeutics, Inc
NEOS
$1.09M 0.43%
+150,000
New +$1.13M
SRPT icon
52
Sarepta Therapeutics
SRPT
$1.77B
$1.01M 0.4%
+30,000
New +$977K
ESRX
53
CALL
DELISTED
Express Scripts Holding Company
ESRX
$958K 0.38%
+15,000
New +$942K
WMGIZ
54
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$857K 0.34%
587,241
– –
AGEN
55
CALL
Agenus
AGEN
$290M
$782K 0.31%
+10,190
New +$717K
AGRX
56
DELISTED
Agile Therapeutics
AGRX
$654K 0.26%
87
+5
+6% +$34.6K
ARNA
57
DELISTED
Arena Pharmaceuticals Inc
ARNA
$590K 0.23%
+35,000
New +$480K
RGNX icon
58
Regenxbio
RGNX
$708M
$569K 0.23%
+28,820
New +$558K
BCRX icon
59
BioCryst Pharmaceuticals
BCRX
$2.4B
$556K 0.22%
+100,000
New +$609K
STML
60
DELISTED
Stemline Therapeutics, Inc.
STML
$552K 0.22%
60,000
– –
ADYX
61
DELISTED
Adynxx Inc
ADYX
$447K 0.18%
20,134
– –
ABCO
62
CALL
DELISTED
Advisory Board Co
ABCO
$227K 0.09%
+4,400
New +$221K
AVEO
63
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$222K 0.09%
+10,000
New +$78.7K
CRVO icon
64
CervoMed
CRVO
$26.6M
$193K 0.08%
+74
New +$238K
XENT
65
CALL
DELISTED
Intersect ENT, Inc
XENT
$126K 0.05%
+4,500
New +$102K
FOMX
66
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$112K 0.04%
24,100
– –
ARAY icon
67
CALL
Accuray
ARAY
$34M
$50K 0.02%
10,500
-39,500
-79% -$174K
OCGN icon
68
Ocugen
OCGN
$434M
$24K 0.01%
225
– –
ABT icon
69
CALL
Abbott
ABT
$187B
– –
-175,000
Closed -$7.77M
ABT icon
70
Abbott
ABT
$187B
– –
-155,000
Closed -$6.88M
ANIP icon
71
ANI Pharmaceuticals
ANIP
$1.78B
– –
-28,875
Closed -$1.43M
ARAY icon
72
Accuray
ARAY
$34M
– –
-685,100
Closed -$3.01M
ARDX icon
73
Ardelyx
ARDX
$997M
– –
-102,500
Closed -$1.3M
CNC icon
74
Centene
CNC
$32.5B
– –
-216,982
Closed -$7.73M
COLL icon
75
Collegium Pharmaceutical
COLL
$956M
– –
-200,000
Closed -$2.01M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM

Pura Vida Investments's Q2 2017 Portfolio in Review

As of Q2 2017, Pura Vida Investments held 113 positions worth $252M, down 26% from $338M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments withdrew a net $109M in Q2 2017, closing 45 positions and reducing 16 holdings. Its most notable exit was Hologic, an estimated $10.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Industrials.

Against the trend, Pura Vida Investments opened a new position in Express Scripts Holding Company worth $11.2M.

  • Pura Vida Investments's largest Q2 2017 buy was Express Scripts Holding Company: 174,700 shares worth $11.2M.
  • Pura Vida Investments added most to NanoString Technologies, Inc. in Q2 2017, an estimated $4.51M increase.
  • Pura Vida Investments's biggest Q2 2017 reduction was Exact Sciences, cutting an estimated $6.94M.
  • Pura Vida Investments fully exited Hologic in Q2 2017, selling an estimated $10.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $252M portfolio in Q2 2017.
  • Pura Vida Investments opened 35 new positions and closed 45 in Q2 2017.
  • Pura Vida Investments's portfolio value fell 26% quarter-over-quarter to $252M.

Based on Pura Vida Investments's 13F filing for Q2 2017, filed 14 Aug 2017.